Novo Nordisk Ups Metsera Bid to $10 Billion to Top Pfizer’s Offer
Novo Nordisk; Metsera; Pfizer; M&A; biotech acquisition; contingent value right; obesity drugs; diabetes treatments
Blackstone Pays Merck $700M to Fund Development of Antibody-Drug Conjugate
Blackstone; Merck; sacituzumab tirumotecan; antibody-drug conjugate; cancer drug development; funding agreement; oncology; royalties
Sarepta’s Duchenne Muscular Dystrophy Drugs Fail Confirmatory Trial, Company Pursues Full FDA Approval Regardless
Sarepta Therapeutics; Duchenne muscular dystrophy; confirmatory trial; AMONDYS 45; VYONDYS 53; Elevidys; FDA approval; clinical trial failure; accelerated approval; statistical significance
UCB Wins First FDA Approval for Ultra-Rare Mitochondrial Disease: Kygevvi for Thymidine Kinase 2 Deficiency (TK2d)
UCB; FDA approval; Kygevvi; mitochondrial disease; Thymidine Kinase 2 deficiency; TK2d; doxecitine; doxribtimine; rare diseases; Orphan Drug; Breakthrough Therapy; Priority Review; Rare Pediatric Disease
TScan Cuts Workforce by 30% While Iovance Advances Amtagvi Program Amid Layoffs
TScan Therapeutics; layoffs; Iovance Biotherapeutics; Amtagvi; tumor-infiltrating lymphocyte (TIL) therapy; melanoma; lung cancer; strategic restructuring; biotech layoffs; cell therapy
Metsera Calls Pfizer’s Threats ‘Nonsense’ as Rift Between Companies Widens
Metsera; Pfizer; Novo Nordisk; merger dispute; litigation; obesity drug acquisition; regulatory approval; Delaware Court of Chancery
Eli Lilly to Invest $3 Billion in New European Factory for Weight-Loss Pill Orforglipron
Eli Lilly; Orforglipron; obesity pill; Leiden Bio Science Park; Netherlands; GLP-1 receptor agonist; manufacturing facility; European market; advanced manufacturing; global supply chain
Recent News: Live at 11 a.m. ET – M&A, FDA, MFN and Collaboration with FT
M&A; FDA; MFN; Financial Times; mergers and acquisitions; drug approval; economics; live news
M42 and Oracle Join Forces to Advance Healthy Longevity and Disease Prevention
M42; Oracle Health; healthy longevity; disease prevention; precision medicine; Emirati Genome Program; pharmacogenomics; electronic health record (EHR); personalized healthcare; UAE
Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors
Life Biosciences; David Guyer; Board of Directors; biotechnology; cellular rejuvenation; epigenetic reprogramming; ER-100; aging; drug development